BL
Insider
Braden Michael Leonard
10% ownerBraden Michael Leonard (10% owner) filed 4 Form 4 reports in the trailing twelve months (1 purchase, 3 sales), most often in ADVM. Across 1 priced purchase filing, the average 21-session return was +36.7% from execution and +1.5% from disclosure (delay-adjusted; derived). The largest single filing was $2.4M of ADVM (574,886 sh across 3 lots, as filed), executed Dec 1 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+36.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+1.5%
same 1 filings, from disclosure
Filings, ttm
4
1 buys · 3 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$6.8M
shares × price, as filed
Last traded
Oct 1
Filed Oct 5
Median ADV $1.7M across their filed names
Impact on $10,000 · 12M
$10,152 (+1.5%)
S&P 500 $10,907 (+9.1%) · 7.6 pts behind
Braden Michael Leonard
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $4.1M
Sells $10.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
3 filings
Sector per market data · by filing · past 12 months
Most traded names
ADVM
ADVM
6 buys · 2 sells
8 filings
ANTXRecent filings
OMPURCHASE
Outset Medical, Inc.
View filing →
$806K228,334 sh × $3.53
Exec Oct 1
Filed Oct 5 · 7:24 PM ET ACRSSALE Aclaris Therapeutics, Inc. View filing → $1.4M
300,000 sh × $4.53
Exec Apr 23
Filed Apr 27 · 5:30 PM ET ADVMSALE Adverum Biotechnologies, Inc. View filing → $2.2M
524,560 sh × $4.19
Exec Dec 4 2025
Filed Dec 5 2025 · 5:30 PM ET ADVMSALE Adverum Biotechnologies, Inc. View filing → $2.4M
574,886 sh across 3 lots
Exec Dec 1 2025
Filed Dec 3 2025 · 5:30 PM ET ASTCSALE ASTROTECH Corp View filing → $1.6M
220,410 sh × $7.13
Exec Oct 3 2025
Filed Oct 7 2025 · 5:30 PM ET ANTXSALE AN2 Therapeutics, Inc. View filing → $2.9M
2,525,000 sh across 3 lots
Exec May 28 2025
Filed May 30 2025 · 5:30 PM ET ANTXSALE AN2 Therapeutics, Inc. View filing → $218K
200,000 sh × $1.09
Exec May 28 2025
Filed Jun 16 2025 · 5:30 PM ET † ADVMPURCHASE Adverum Biotechnologies, Inc. View filing → $1.0M
350,000 sh across 2 lots
Exec Apr 22 2025
Filed Apr 24 2025 · 5:30 PM ET More filings →